{"id":12959,"date":"2010-02-03T10:00:00","date_gmt":"2010-02-03T09:00:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/ucb-esce-dal-mercato-primary-care-americano\/"},"modified":"2010-02-03T10:00:00","modified_gmt":"2010-02-03T09:00:00","slug":"ucb-esce-dal-mercato-primary-care-americano","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ucb-esce-dal-mercato-primary-care-americano\/","title":{"rendered":"Ucb exits the American Primary Care market"},"content":{"rendered":"<p><img decoding=\"async\" style=\"width: 100px\" id=\"DLImmagini__ctl302_Img\" border=\"0\" alt=\"\" width=\"100\" src=\"http:\/\/www.informatori.aiisf.it\/img\/Archivio\/\/N3727.jpg\" \/>&nbsp;&nbsp; <span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">The Belgian UCB exits the primary care market in the United States, to focus on specialist therapeutic areas such as immunology and neurology. The decision will be effective as of March 1, 2010. <\/p>\n<p><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 0pt; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">The company will therefore transfer commercial responsibility for some of its &#039;generalist&#039; products to other companies: the anti-allergy Xyzal will pass to Sanofi-aventis and the anti-asthma ProAir HFA to Teva. <\/p>\n<p><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 0pt; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">Instead, it will continue to support the promotion of the anti-tussive Tussionex. &quot;We are deeply grateful to the American primary care team - comments the president of UCB North America, Greg Duncan - because its ten-year work has strengthened the company&#039;s position and success&quot;.<\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 0pt; mso-layout-grid-align: none\" class=\"MsoNormal\" \/>\n<p style=\"margin: 0cm 0cm 0pt; mso-layout-grid-align: none\" class=\"MsoNormal\">&nbsp;<\/p>\n<p style=\"margin: 0cm 0cm 0pt; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\"><\/p>\n<p>PharmaKronos \u2013 03 February 2010<\/p>\n<p><\/font><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp;&nbsp; La belga Ucb esce dal mercato della primary care negli Stati Uniti, per focalizzarsi su aree terapeutiche specialistiche come l&#8217;immunologia e la neurologia. La decisione sar&agrave; operativa a partire dal 1 marzo 2010. La societ&agrave; ceder&agrave; dunque la responsabilit&agrave; commerciale di alcuni dei suoi prodotti &#8216;generalisti&#8217; ad altre aziende: l&#8217;antiallergico Xyzal passer&agrave; a Sanofi-aventis &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12959","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12959"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12959\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}